US 11,866,764 B2
Method for testing and screening p38 MAP kinase modifiers
Gideon Dreyfuss, Wynnewood, PA (US); and Mumtaz Kasim, Philadelphia, PA (US)
Assigned to THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA (US)
Filed by THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA (US)
Filed on Aug. 10, 2020, as Appl. No. 16/989,835.
Application 15/936,027 is a division of application No. 12/663,174, granted, now 9,926,588, issued on Mar. 27, 2018, previously published as PCT/US2008/006973, filed on Jun. 4, 2008.
Application 16/989,835 is a continuation of application No. 15/936,027, filed on Mar. 26, 2018, granted, now 10,738,345.
Claims priority of provisional application 60/924,882, filed on Jun. 4, 2007.
Prior Publication US 2022/0010357 A1, Jan. 13, 2022
Int. Cl. A61K 31/496 (2006.01); A61P 25/28 (2006.01); C12Q 1/48 (2006.01); C07D 241/04 (2006.01)
CPC C12Q 1/485 (2013.01) [A61P 25/28 (2018.01); A61K 31/496 (2013.01); C07D 241/04 (2013.01); G01N 2500/10 (2013.01)] 4 Claims
 
1. A method of treating or inhibiting a disease in a subject, comprising administering to said subject a compound having a structure according to Formula (I):

OG Complex Work Unit Chemistry
wherein R1 is a substituted or unsubstituted, 5-6 membered carbocyclic or heterocyclic aromatic ring, wherein said ring is directly attached to the carbonyl substituent of the piperazine ring in Formula (I);
R2 is a substituted or unsubstituted, carbocyclic or heterocyclic, 5-6 membered aromatic ring; and
X1 is S and X2 is O, wherein said disease is associated with elevated p38 mitogen-activated protein kinase (MAPK) enzymatic activity in a cell in said subject, thereby treating or inhibiting said disease in said subject.